From the New Yorker article today on the economics of Ebola (introducing a new word, Ebolanomics):
What people in the West need, health officials agree, is new drugs that we can keep in reserve against an outbreak that regular antibiotics can’t contain.
The article suggests prizes and delinkage (paying for R&D without linking revenues to volume), quoting me.
Chatham House paper here (Chatham House website) or here (SSRN); Yale J Health Policy, Law & Ethics here; the Strategic Antimicrobial Reserve is also discussed in this 2010 Health Affairs paper.
@koutterson
